EFATUTAZONE DIHYDROCHLORIDE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C27H26N4O4S.2ClH
Molecular Weight	575.507
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of EFATUTAZONE DIHYDROCHLORIDE

Structure Search

SMILES

Cl.Cl.CN1C(COC2=CC=C(CC3SC(=O)NC3=O)C=C2)=NC4=C1C=C(OC5=CC(C)=C(N)C(C)=C5)C=C4

InChI

InChIKey=WFIOHOJEIMQCEG-UHFFFAOYSA-N

InChI=1S/C27H26N4O4S.2ClH/c1-15-10-20(11-16(2)25(15)28)35-19-8-9-21-22(13-19)31(3)24(29-21)14-34-18-6-4-17(5-7-18)12-23-26(32)30-27(33)36-23;;/h4-11,13,23H,12,14,28H2,1-3H3,(H,30,32,33);2*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C27H26N4O4S
Molecular Weight	502.585
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://adisinsight.springer.com/drugs/800024172 | https://www.cancer.gov/publications/dictionaries/cancer-drug/def/efatutazone-dihydrochloride

Efatutazone (CS-7017 or RS-5444) is a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with antineoplastic properties. Mediated through activation of PPAR-gamma, this agent is capable of inducing cell differentiation and apoptosis, thereby leading to a reduction in cellular proliferation. Efatutazone was in clinical trials for the treatment of solid tumors however; its development has been discontinued.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor gamma 118 Target ID: P37231\|\|\|Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23589525	Agonist 2752

PubMed

Title	Date	PubMed
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.	2013-06	23589525
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.	2012-11-01	22570147

Patents

Sample Use Guides

In Vivo Use Guide

Phase I trial: 0.10 to 1.15 mg PO twice daily.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:42:23 GMT 2025` Edited by `admin` on `Mon Mar 31 19:42:23 GMT 2025`
Record UNII	76B44WEA8O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EFATUTAZONE DIHYDROCHLORIDE

Common Name

English

CS-7017

Preferred Name

English

2,4-THIAZOLIDINEDIONE, 5-((4-((6-(4-AMINO-3,5-DIMETHYLPHENOXY)-1-METHYL-1H-BENZIMIDAZOL-2-YL)METHOXY)PHENYL)METHYL)-, HYDROCHLORIDE (1:2)

Systematic Name

English

INOLITAZONE DIHYDROCHLORIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1934